5th Letter to Shareholders

Discover OPM’s 5th Letter to Shareholders!

Focus sur

• Focus on the submission of the Phase 1b/2a REVERT clinical study and the Testimonial from Prof. Olivier Michielin, main coordinator of the REVERT study
• Inhibition of RIPK2: a new immunotherapy approach for advanced cancers
• The creation of the PROMETHE association